This study is testing a new treatment called BS01 for people with Retinitis Pigmentosa, an eye disease that causes vision loss. BS01 is a gene therapy that uses a modified virus to deliver a light-sensitive gene into the eye. The goal is to see if BS01 is safe and effective in improving vision. To join, you must have a confirmed diagnosis of Retinitis Pigmentosa and vision no better than 20/160 in at least one eye, or significant peripheral vision loss. The study aims to enroll 20 participants, but its current status is unclear. Researchers will measure the main outcome at 12 months to see how well the treatment works.

Study design

This is a Phase 1/2 interventional study, meaning it's an early-stage trial looking at safety and effectiveness. It plans to enroll 20 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for at least 12 months to assess the primary outcome.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.